| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911441 | Lung Cancer | 2011 | 5 Pages |
Abstract
Obatoclax mesylate added to topotecan does not exceed the historic response rate seen with topotecan alone in patients with relapsed SCLC following the first-line platinum-based therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paul K. Paik, Charles M. Rudin, Maria C. Pietanza, Andrew Brown, Naiyer A. Rizvi, Naoko Takebe, William Travis, Leonard James, Michelle S. Ginsberg, Rosalyn Juergens, Susan Markus, Leslie Tyson, Sara Subzwari, Mark G. Kris, Lee M. Krug,